Clinical trial
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
NCT00404352 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00404352 |
|---|---|
| Title | REbif FLEXible Dosing in Early Multiple Sclerosis (MS) |
| Official title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX) |
| Acronym | REFLEX |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | RNF, Placebo |
| Enrollment | 517 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Nov 28, 2006 |
| Last update posted | Jan 24, 2014 |
| Countries | Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland, France, Germany and 15 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: